Dario A. Vignali, PhD
Campus: 200 Lothrop Street
Office: E1052 BSTWR
Lab: E1000-12B - 15A
Pittsburgh PA 15261
- BSc, Immunology and Medical Microbiology, North East London Polytechnic, 1985
- PhD, Immunology of Infectious Diseases, University of London, 1988
- Professor and Vice Chair
- Leader of the Cancer Immunology Program
- Co-Director of the Tumor Microenvironment Center
- Scientific Director of Fondazione Ri.MED
Our research focuses on various aspects of T cell regulation and function:
(1) Mechanistic Focus:
(a) Immune Regulation: Regulatory T cells (Tregs): Identification of novel Treg molecules and their function; mechanism of Treg function; regulation of Treg stability via Nrp1 and other pathways; IL-35 signaling and mechanism of action; IL-35 production by other cell populations.
(b) Immune Regulation: Inhibitory Molecules: Identification of novel inhibitory mechanisms; immune modulation of T cell subsets by LAG3 and PD1; synergy between LAG3 and other inhibitory receptors, particularly PD1.
(c) Control of T cell receptor (TCR):CD3 complex signaling: Modulation and control of TCR signal transduction by inhibitory receptors and mechanisms; mechanism of TCR:CD3 signaling.
(2) Disease Focus:
(a) Cancer: Biology of LAG3/PD1, IL-35 and Nrp1 in mouse models of cancer and also in samples from treatment-naive patients or immunotherapy recipients; primary focus on solid tumors – head & neck, melanoma, lung, pancreatic, ovarian cancer, with some work on breast, GI and glioma cancers, and hematological malignancies; novel approaches for therapeutic translation.
(b) Autoimmune and Inflammatory Disease: Impact and function of Tregs and inhibitory receptors in the several autoimmune and inflammatory disease with emphasis on models of autoimmune diabetes (NOD mouse model), EAE and asthma; development of approaches to enhance Treg stability and function; therapeutic delivery approaches to promote IL-35, Nrp1 and Lag3 function.
Abigail E. Overacre-Delgoffe, Maria Chikina, Rebekah E. Dadey, Hiroshi Yano, Erin A. Brunazzi, Gulidanna Shayan, William Horne, Jessica M. Moskovits, Jay K. Kolls, Cindy Sander, Yongli Shuai, Daniel P. Normolle, John M. Kirkwood, Roberty L. Ferris, Greg M. Delgoffe, Tullia C. Bruno, Creg J. Workman, Dario A.A. Vignali (2017). Interferon-y Drives Treg Fragility to Promote Anti-tumor Immunity. Cell 169:6 1130-1141.
Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, Normolle D, Bettini M, Workman CJ, Vignali DAA (2017). LAG-3 limits regulatory T cell proliferation and function in autoimmune diabetes. Science Immunology. In Press.
Turnis ME*, Sawant DV*, Szymczak-Workman A, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DAA (2016). Interleukin-35 limits anti-tumor immunity. Immunity 44: 316-329 [PMCID: 4758699].
Guy C, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai Y-H, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DAA. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nature Immunology 14:262-270, 2013. [Issue cover] [PMCID: 3577985].
Delgoffe GM*, Woo SR*, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, Workman CJ, Vignali DAA. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 2013 Sep 12; 501(7466):252-256 [PMCID: 3867145].
Vignali DAA, Kurchroo VK (2012). IL-12 Family Cytokines: Immunlogical Playmakers. Nature Immunology 13: 722-728 [PMID: 22814351; PMCID: 4158817].
Collison LC*, Delgoffe GM*, Guy C, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DAA (2012). The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology 13: 290-299 [PMCID: 3529151].
Woo S-R*, Turnis ME*, Goldberg MV*, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Vogel P, Liu C-L, Tangsombatvisit S, Grosso, JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DAA (2012). Immune inhibitory molecular LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Research 72: 917-927 [PMCID: 3288154].
Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni H-T, Artis D, Turk MJ, Vignali DAA (2010). Interleukin-35-mediated induction of a potent regulatory T cell population. Nature Immunology 11: 1093-1101 [PMCID: 3008395].
Vignali DAA, Collison LW, Workman CJ (2008). How regulatory T cells work. Nature Reviews Immunology 8: 523-532 [PMID: 18566595; PMCID: 2665249].
Holst J, Wang H, Durick-Eder K, Workman CJ, Boyd K, Baquet Z, Singh H, Forbes K, Chruscinski A, Smeyne R, van Oers NSC, Utz PJ, Vignali DAA (2008). Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nature Immunology 9: 658-666 [PMID: 18469818].
Collison LW, Workman CJ, Kuo TK, BOyd K, Wang Y, Vignali K, Cross R, Sehy D, Blumberg RS, Vignali DAA (2007). The inhibitory cytokine IL-35 contributes to regulatory T cell function. Nature 450: 566-569 [PMID: 18033300].
Holst J, Vignali KM, Burton AR, Vignali DAA (2006). Rapid analysis of T cell selction and function in vivo using T cell receptor retrogenic mice. Nature Methods 3: 191-197 [PMID: 16489336].
Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin E, Vignali DAA (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nature Biotechnology 22: 589-594 [PMID: 15064769].
- Our research focuses on gaining a better understanding of the inhibitory mechanisms, including inhibitory receptors and regulatory T cells, that limit anti-tumor immunity in cancer patients.
- We also have discovery-based programs aimed at identifying novel targets for therapeutic intervention.
- We are also working with UPCI scientists and clinicians to facilitate the translation of novel therapeutic modalities with a focus on immunologically-impacted solid tumors (primarily head and neck, melanoma, lung, pancreatic cancer).
- My UPCI leadership efforts are directed toward providing a bridge between basic and transitional cancer immunology.
- We work extensively with large and start-up biopharmaceutical companies to bring novel therapeutics to the clinic.